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Fibromyalgia syndrome (FM) is a chronic condition that is 
dominated by widespread pain, but presents with a complex of symptoms 
that include fatigue, dysfunctional sleep and cognitive disruption [1]. 
Patients have been diagnosed in most countries across the world with a 
prevalence of FM estimated to be 2 – 4% of the population. Progress has 
recently been made in understanding aspects of the pathophysiology 
and identiication of efective treatments of FM [1,2], although there is 
still a reliance on the subjectivity of symptom proiles as identiied by 
the American College of Rheumatology (ACR) criteria for diagnosis [3]. 
he pathophysiology of FM has been suggested to involve dysfunction 
of the central nervous system pain modulatory systems leading to 
central sensitization, dysfunction of the neuroendocrine system and 
dysautonomia [1,2]. Neuroimaging has indicated abnormalities in 
regional cerebral blood low, in the white and gray matter and the brain 
metabolites (glutamate, glutamine, creatine and N-acetyl-aspartate) in 
individuals with FM [4]. he complexity of symptoms that results is 
then associated with a heightened generalized sensitization to sensory 
input.
he current therapeutic approach to improve health status in 
FM is a multi-modal rehabilitation model, integrating exercise, 
behavioural/management programs and pharmacological treatment; 
however, a universally accepted treatment algorithm is oten lacking 
[1,5]. A diversity of physical and psychological characteristics of the 
symptoms suggestive of a heterogeneous population of patients further 
complicates the treatment approach [6]. In addition, the relative lack of 
reliability of the application of the ACR criteria, which has aspects that 
overlap with many symptoms of other health conditions (eg chronic 
fatigue syndrome, ME, myofascial pain), for the diagnosis of FM may 
miss patients [7]. 
Although a variety of treatment modalities have demonstrated an 
improvement in health status in patients with FM in clinical trials, the 
outcomes are oten limited and only beneit a proportion of the subjects. 
he efectiveness of the diferent approaches is oten short-lived and 
large variations in treatment response have been cited [8,9]. Many 
drugs with pharmacologically diferent mechanisms have demonstrated 
efectiveness in subgroups of FM patients, but no single drug has 
addressed the complete range of FM symptoms nor met the needs of 
all patients consistent with a heterogeneity of the patient population 
[9,10]. Drug treatment remains largely empiric with the condition 
being managed through targeting individual symptoms where results 
are highly variable and long-term prospective observational studies 
have found that outcomes are typically poor. Consequently, current 
medications are either insuicient to control the symptoms of many 
patients or diicult to tolerate oten due to an apparent high sensitivity 
to adverse efects of drugs. A high rate of discontinuation (33 – 42%) 
has been observed in FM phase 3 clinical trials [1]. hus, the majority 
of patients with FM only obtain modest relief to drug treatments and 
general compliance is low.
A number of drugs are currently in development for FM relecting 
the interest by the pharmaceutical industry into this condition [9,10]. 
For the majority of drugs that have been or are currently in clinical trials 
for FM, however, this condition (and thereby the patient population) is 
secondary to that for which the compound has been initially developed 
or approved. he lack of understanding of the pathophysiology of 
FM has prevented the availability of clues for the rational design of 
mechanistically based drug treatment approaches. As a consequence, 
attempts to identify new therapies involve either the assessment 
of existing therapeutic strategies with the potential of improving 
tolerability, or evaluation of drugs that have previously demonstrated 
eicacy in another condition for a symptom associated with FM [1,9]. 
he successes of many of the clinical trials have been limited by the 
complexities of FM. he identiication of viable speciic drug targets 
has been hindered by the limited understanding of the pathophysiology 
of FM and previous diiculty in achieving good drug eicacy in such a 
heterogeneous patient population.
Many of the clinical trials of potential drug treatments, however, 
have common limitations and may be criticized for evaluating a 
population that may not be representative of the general FM population 
which inluence the outcomes. he chronic nature of FM and large 
intrinsic variability of symptoms, particularly pain, over short periods 
of time requires pharmacological therapies with long-term eicacy 
which may not be observed across all symptoms within the irst few 
weeks of treatment, consequently short-term trials (eg up to 12 weeks) 
will not provide clinically applicable outcomes [1,9-11]. Although 
evidence from clinical studies indicates that certain pharmacological 
agents, eg pregabalin and duloxetine, can provide meaningful beneit 
in FM within one to two weeks with early improvement being a 
predictor of treatment outcome, proof of adequate long-term eicacy 
requires attention [12]. Durability of beneit has oten been in restricted 
cohorts (through selective inclusion criteria; eg gender), involving 
extension studies that have been deined by the restricted criteria of 
the initial trial. Many clinical trials involved the use of relatively small 
patient numbers and as a consequence the outcomes are complicated 
by the heterogeneity of the patient population and proposals that there 
could be subgroups of patients with FM. An increase in the duration 
(12 months and greater) and cohort size of trials will provide a more 
realistic representation of the clinical setting and should not be solely to 
improve statistical signiicance for perhaps a weak therapy [13]. 
he exclusion of patients with other pain conditions and the use 
of certain analgesics or other medications is common practice to 
avoid confounding the interpretation of data as well as reporting of 
adverse efects. Co-morbidities, such as osteoarthritis or rheumatoid 
arthritis, depression, irritable bowel syndrome, however can be 
the norm rather than the exception with FM in clinical practice, 
but patients with co-morbidities are oten excluded from clinical 
trials. his focus to simplify studies, perhaps because of the limited 
understanding of FM, rather than the requirement of the condition will 
understandably dictate the outcomes. Again, this is further confounded 
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by studies evaluating populations (predominantly female, middle aged, 
Caucasian, overweight and with symptoms for approximately 10 years) 
not necessarily representing clinical practice [14].
Pain management has oten been a single or the primary symptom 
endpoint of trials in FM with limited consideration of other symptoms 
[1,8,9], however a more frequent involvement of quality of life 
assessment is being recognised. Although the clinician-investigators’ 
identiied core domains as most important for assessment in FM studies 
has oten been primarily focused on reducing pain, an OMERACT 
(Outcome Measures in Rheumatology) Delphi exercise identiied 
several other important patient-reported concerns (e.g. fatigue, sleep 
disturbance, stifness, poor concentration and disorganised thinking) 
[15]. he practicality or availability of assessment of the domains rather 
than relevance to the condition may oten inluence the incorporation 
within clinical trial protocols. hus directing treatment strategies 
toward a broad variety of FM symptoms is suggested by these patient-
reported concerns. he range of FM symptoms and their severity, and 
the presence of co-morbidities need to be taken in to consideration 
where the management of patients requires an individualized treatment 
approach. 
Monotherapy randomized placebo-controlled clinical trials in 
FM have only allowed identiication of marginal improvements in the 
clinical state. Investigation of a single therapy approach in the design 
of FM clinical trials is not representative of clinical practice where 
pharmacological and non-pharmacological treatments are incorporated 
as combination therapies [1,5]. he development of lexible or adaptive 
design would enable trials to be more representative for the patient 
population with this complex condition (i.e. several luctuating 
symptom domains, various co-morbidities) with the necessity of multi-
therapy approaches [13]. he success of such therapies will give clues to 
the biology associated with FM and this will lead to the development 
of more robust and universally accepted diagnostic tools. Improved 
diagnosis in combination with the development of condition, rather 
than symptom-focused, therapies will lead to further advancement in 
clinical trial design. 
herefore there is a need for more naturalistic larger studies, 
which include patients with various medical co-morbidities, involve 
concurrent therapies, to address the chronic nature of the condition and 
to achieve better informed decisions between alternative treatments.
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